Oregon Health and Science University
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Oregon Health and Science University sits in the top decile of US sponsors by registered trial count (#67 of 15,742 sponsors by registered trial count).
Oregon Health and Science University: 546 sponsored US clinical trials, 91 recruiting.
Oregon Health and Science University sponsors 546 registered US clinical trials on ClinicalTrials.gov, 91 of them currently recruiting, and 370 completed. 73 of these trials are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.
Top-decile sponsor footprint
Oregon Health and Science University ranks in the top decile of sponsors by registered trial count (#67 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
370 of 420 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
546 total, page 11 of 11
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
NCT00415506
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
NCT00806221
Clinical Study of the U-Plate Fracture Repair System to Treat Rib Fractures
NCT00556543
Hypothalamic Functional Magnetic Resonance Imaging (fMRI) Response to Nutrients
NCT00686608
Lucentis (Ranibizumab) for Eales' Disease
NCT00384449
Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)
NCT00694759
A Motivational Enhancement Approach to Skin Cancer Prevention
NCT00705887
Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
NCT00654004
Energy Expenditure and Gastric Bypass Surgery Study
NCT00671957
Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates
NCT00517062
Oral Contraceptive Efficacy and Body Weight
NCT00662454
Measuring Preferences for Childbirth After Cesarean
NCT00267735
A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis
NCT00676156
Medications for the Treatment of Dysthymic Disorder and Double Depression
NCT00234312
American Ginseng Treatment for Multiple Sclerosis Related Fatigue
NCT00754832
Expectation and Response to Levodopa and Acupuncture in Parkinson's Disease
NCT00692328
Dietary Lutein and the Retinopathy of Prematurity
NCT00672230
Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients
NCT00110552
Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis
NCT00122954
Uveitis Gene-Expression Profiling
NCT00874471
Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
NCT00131469
Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
NCT00260299
A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
NCT00212758
Changing Healthy Outcomes In Clinic Environments
NCT00674518
Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome
NCT00129792
Young Blind Child Melatonin Treatment Study
NCT00688935
Blind Elderly Melatonin Treatment Study
NCT00692094
Methylphenidate and Parkinson's Disease
NCT00359723
Determinants of Surgical Outcomes in Chronic Sinusitis
NCT00799097
MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
NCT00659776
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
NCT00300716
Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease
NCT00090402
Pilot Trial of a Behavioral Treatment for Epilepsy
NCT00212745
Advanced Imaging for Glaucoma Study
NCT01314326
Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease
NCT00666653
Providing Birth Control Through Home Health Visits
NCT00065078
Testing Mestinon and Exercise in Fibromyalgia
NCT00535587
Blind Child Melatonin Treatment Study
NCT00691444
Effectiveness of Supplemental Calcium in Preventing Postpartum Depression
NCT00228033
Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants
NCT00669383
The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation
NCT00688987
Promoting Healthy Lifestyles Among Firefighters
NCT00006181
Melatonin Levels in Smith Magenis Syndrome (SMS)
NCT00691574
Melatonin for Circadian Sleep Disorders in the Blind
NCT00911053
Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?
NCT00120913
4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions
NCT00121329
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 40 |
| Phase 3 | 6 |
| Phase 4 | 67 |
Therapeutic Areas
What is open in the Oregon Health and Science University pipeline
91 recruiting of 546 indexed (17% open); 370 completed (68%).
Phase mix: 73 late (III/IV) vs 92 early (I/II) (balanced across stages).
Top condition: Obesity (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Oregon Health and Science University: open-pipeline peers nationwide
Peers matched on 546 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Oregon Health and Science University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 546 trials (± recruiting share)
- Ohio State University · 552 trials · 21% recruiting
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Oregon Health and Science University page
546 registered trials is a research-attention snapshot, not an endorsement of Oregon Health and Science University or any single study.
- 91 of Oregon Health and Science University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Oregon Health and Science University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Oregon Health and Science University pipeline card: 546 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.